PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18413496-4	2008	Pioglitazone treatment led to improvement in levels of multiple cardiovascular risk markers, including high-sensitivity C-reactive protein, apolipoprotein B, apolipoprotein A1, high-density lipoprotein (HDL) cholesterol, triglyceride, insulin, and free fatty acid.	Pioglitazone	0-12	apolipoprotein B	Homo sapiens	140-156	
19646194-7	2009	There was a decrease in VLDL triglyceride/apoB (P = 0.04) in the pioglitazone group.	Pioglitazone	65-77	apolipoprotein B	Homo sapiens	42-46	
16644631-8	2006	At week 12, muraglitazar and pioglitazone reduced mean plasma triglyceride (-28 vs. -14%), apolipoprotein B (-12 vs. -6%), and non-HDL cholesterol (-6 vs. -1%) and increased HDL cholesterol (19 vs. 14%), respectively (P < 0.0001 vs. pioglitazone for all comparisons).	Pioglitazone	29-41	apolipoprotein B	Homo sapiens	91-107	
17229249-7	2007	Significant total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and apolipoprotein B improvement was observed in pioglitazone group after 12 months, but not in the rosiglitazone group.	Pioglitazone	190-202	apolipoprotein B	Homo sapiens	145-161	
12809958-11	2003	Pioglitazone 45 mg also significantly reduced serum triglycerides, apolipoprotein B, and total cholesterol:HDL-C ratio versus placebo (P = 0.007, P = 0.015, and P = 0.005, respectively).	Pioglitazone	0-12	apolipoprotein B	Homo sapiens	67-83	
12466345-9	2002	HDL-cholesterol was increased and apolipoprotein B was decreased to a significantly greater extent with pioglitazone.	Pioglitazone	104-116	apolipoprotein B	Homo sapiens	34-50